ClinicalTrials.gg
TerminatedNCT00294541Updated Sep 11, 2007

A Study Evaluating the Long-Term Safety of ICA-17043 in Sickle Cell Disease Patients With or Without Hydroxyurea Therapy

A Phase 3 interventional study of ICA-17043 in Sickle Cell Disease and Sickle Cell Anemia, sponsored by Icagen. Terminated at 31 sites in United States. Open to participants aged 17 Years to 66 Years. Per ClinicalTrials.gov, last updated 2007-09-11.

Sponsored by Icagen · Phase 3, Interventional, and Treatment

Why this study was terminated
Lack of efficacy demonstrated in study ICA-17043-10

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
51
Allocation
Non-randomized
Ages
17 Years to 66 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 733 studies in Anemia, Sickle Cell with a site in United States — 134 open to participants now, 185 under way, 16 of them phase 3. Anemia, Sickle Cell · United States.

Enrollment
192nd of 559
51 · median 31
Started
2006
with 13 others
Phase 3
50 of 733
10 open now
Registered
57th of 733
by date

Among the 733 studies in Anemia, Sickle Cell with a site in United States, this one is the 192nd largest by enrollment of the 559 interventional ones that give a count, is one of 14 that started in 2006, is one of 50 in phase 3, and was the 57th registered.

Anemia, Sickle Cell

1,134 studies on the registry are indexed under Anemia, Sickle Cell; 238 are open to participants now.

Browse Anemia, Sickle Cell studies →

Open to participants now

134 of the 733 studies in Anemia, Sickle Cell with a site in United States are open now. Recruiting first, the newest first:

129 more — sign in →

All 134 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 177 Anemia, Sickle Cell studies recruiting now, 64 (36%) set no upper age limit and 97 (55%) stop at 75 or younger; 127 take children under 18; 29 take healthy volunteers.

This study: 17 Years to 66 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 733 studies in Anemia, Sickle Cell with a site in United States, or all of them as a file.
02

Study summary

This trial is a follow-up companion study to Protocol ICA-17043-10, a Phase III, multi-center, efficacy and safety study of ICA-17043. This is an open-label extension study collecting safety data on the use of ICA-17043 in subjects with sickle cell disease (SCD) (e.g., HbSS, HbSC, HbSb0-thalassemia, HbSb+-thalassemia subjects). All subjects who have successfully completed ICA-17043-10 will, if deemed appropriate by their study Investigator and appropriate consent by subject is given, enroll in the ICA-17043-12 study (Study 12). Only patients who participated in ICA-17043-10 are eligible for this open label study

03

Conditions studied

  • Sickle Cell Disease
  • Sickle Cell Anemia

Browse trials for

Keywords

  • sickle cell disease
  • sickle cell anemia
04

Who can participate

Ages eligible
17 Years to 66 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Successfully completed Study ICA-17043-10
  • Discontinued Study 10 or 12 following the DMC recommendations because he/she was not on HU, and has since been on a stable dose of HU for at least 3 months prior to Day 1
  • Male, or female not capable of becoming pregnant or using appropriate
  • Has willingly given written to participate in this study

Exclusion criteria

Exclusion Criteria:

  • The subject, if female, has a positive urine pregnancy test on Day 1 (before entering study)
  • The subject is presently unsuitable for participation in this long-term study
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
51 participants (actual)

Interventions

06

What researchers measure

Primary outcomes

  1. Safety measures only

    Time frame: at least 60 weeks

  2. No efficacy outcome measures

07

Study locations

31 sites
  • University of South Alabama
    Mobile, Alabama 36617, United States
  • Arkansas Children's Hospital
    Little Rock, Arkansas 72202, United States
  • Children's Hospital Oakland
    Oakland, California 94609, United States
  • University of California Davis Medical Center
    Sacramento, California 95817, United States
  • University of Colorado Health Sciences Center
    Denver, Colorado 80262, United States
  • Century Clinical Research, Inc.
    Holly Hill, Florida 32117, United States
  • University of Florida Health Science Center
    Jacksonville, Florida 32209, United States
  • Medical College of Georgia
    Augusta, Georgia 30912, United States
  • Memorial Health University Medical Center
    Savannah, Georgia 31404, United States
  • University of Illinois Medical Center
    Chicago, Illinois 60612, United States
  • Sickle Cell Center of Northern Louisiana
    Shreveport, Louisiana 71103, United States
  • Johns Hopkins University School of Medicine
    Baltimore, Maryland 21205, United States
  • Brigham and Women's Hospital
    Boston, Massachusetts 02115, United States
  • Wayne State School of Medicine
    Detroit, Michigan 48201, United States
  • University of Mississippi Medical Center
    Jackson, Mississippi 39216, United States
  • Hackensack University Medical Center
    Hackensack, New Jersey 07601, United States
  • Robert Wood Johnson Medical Center
    New Brunswick, New Jersey 08903, United States
  • Newark Beth Israel Medical Center
    Newark, New Jersey 07112-2027, United States
  • SUNY Downstate Medical Center
    Brooklyn, New York 11203, United States
  • New York Methodist Hospital
    Brooklyn, New York 11215, United States
  • University of North Carolina Hospitals
    Chapel Hill, North Carolina 27514, United States
  • Duke University Medical Center
    Durham, North Carolina 27710, United States
  • East Carolina University School of Medicine
    Greenville, North Carolina 27858, United States
  • Wake Forest University School of Medicine
    Winston-Salem, North Carolina 27157, United States
  • University of Cincinnati
    Cincinnati, Ohio 45219, United States
  • Thomas Jefferson University Hospital
    Philadelphia, Pennsylvania 19107, United States
  • St. Christopher's Hospital for Children
    Philadelphia, Pennsylvania 19134-1095, United States
  • Medical University of South Carolina
    Charleston, South Carolina 29425, United States
  • Baylor College of Medicine
    Houston, Texas 77030, United States
  • Medical College of Virginia
    Richmond, Virginia 23298-0157, United States
  • Virginia Commonwealth University
    Richmond, Virginia 23298, United States
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2006 and a completion of Jun 2007. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 21, 2006
First posted
Feb 22, 2006
Start
Feb 2006
CompletionActual
Jun 2007
Last update
Sep 11, 2007
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 11, 2007, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00294541
Lead sponsor
Icagen
First posted
Feb 22, 2006
Start date
Feb 2006
Completion
Jun 2007
Last update
Sep 11, 2007

Study contacts

Jonathan W Stocker, PhD
study director · Icagen

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Sep 2007. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Senicapoc

Start the discussion